A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

16720GCT1184-03-RAINFOL-03OpenA Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy GCT1184-03 (GOG-3128)NCT07166094IndustrialAdultTreatmentIIICervixHoskins, EbonyMedStar Health and GUMC; Medstar Washington Hospital Center : Reva PersaudGyn. Onc.Oncology GroupMHRI Washington Cancer Institute17525Reva PersaudReva PersaudReva.S.Persaud@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>